US OptionsDetailed Quotes
RPTX241220P2500
- 0.85
- +0.80+1600.00%
15min DelayClose Dec 13 15:59 ET
0.86High0.20Low
0.20Open0.05Pre Close179 Volume153 Open Interest2.50Strike Price7.52KTurnover366.31%IV6.78%PremiumDec 20, 2024Expiry Date0.73Intrinsic Value100Multiplier5DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type-0.7027Delta0.4311Gamma2.08Leverage Ratio-0.0251Theta-0.0003Rho-1.46Eff Leverage0.0008Vega
Repare Therapeutics Stock Discussion
Sign in to post a comment
$Repare Therapeutics (RPTX.US)$ lets crack 1.80 and at least hold
1
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
1
3
NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...
*************************************
REVERSE...
58
8
my friend
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
3
10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
1
$Repare Therapeutics (RPTX.US)$ Reuters· 4 mins ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial
2
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE
$Mill City Ventures III (MCVT.US)$ $Jowell Global (JWEL.US)$ $NCI (01336.HK)$ $Onconetix (ONCO.US)$ $YXT.COM Group Holding (YXT.US)$ $Cognition Therapeutics (CGTX.US)$ $Ambow Education (AMBO.US)$ $Matinas BioPharma (MTNB.US)$ $TCTM Kids IT Education (TCTM.US)$ $N2OFF (NITO.US)$ $Repare Therapeutics (RPTX.US)$ $ZK International (ZKIN.US)$
📊⚡️📊
📊⚡️📊
2
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations.
The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with va...
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations.
The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with va...
No comment yet
the MONEY drifter : Never thought it would fall down this low at the open market. Hopefully it will recover in the coming days.